These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 18262501

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ.
    Int J Cancer; 2007 Feb 01; 120(3):563-5. PubMed ID: 17096342
    [Abstract] [Full Text] [Related]

  • 3. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.
    Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, Rodero M, Carpentier C, Paris S, Laigle-Donadey F, Ducray F, Hoang-Xuan K, Delattre JY.
    Cancer Genet Cytogenet; 2007 Sep 01; 177(2):103-7. PubMed ID: 17854663
    [Abstract] [Full Text] [Related]

  • 4. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
    Okishiro M, Kim SJ, Tsunashima R, Nakayama T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.
    Breast Cancer Res Treat; 2012 Apr 01; 132(3):947-53. PubMed ID: 21706156
    [Abstract] [Full Text] [Related]

  • 5. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H.
    Breast Cancer Res; 2009 Apr 01; 11(6):R89. PubMed ID: 20021639
    [Abstract] [Full Text] [Related]

  • 6. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ, Broeks A, Horlings HM, Canisius SV, Braaf LM, Langerød A, Van't Veer LJ, Schmidt MK.
    Breast Cancer Res Treat; 2011 Nov 01; 130(2):599-608. PubMed ID: 21667122
    [Abstract] [Full Text] [Related]

  • 7. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ, Fang C, Fan L, Zhu DX, Wang DM, Zhu HY, Zhuang Y, Miao KR, Liu P, Xu W, Li JY.
    Int J Cancer; 2012 May 01; 130(9):2054-61. PubMed ID: 21647873
    [Abstract] [Full Text] [Related]

  • 8. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I.
    J Clin Oncol; 2008 May 10; 26(14):2252-7. PubMed ID: 18467716
    [Abstract] [Full Text] [Related]

  • 9. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4123-9. PubMed ID: 17634539
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP, Wong RH, Cheng YW, Chen CY, Lee H.
    Ann Surg Oncol; 2010 Apr 15; 17(4):1194-202. PubMed ID: 19941079
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.
    Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT.
    Cancer Genet Cytogenet; 2009 Nov 15; 195(1):31-6. PubMed ID: 19837266
    [Abstract] [Full Text] [Related]

  • 14. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, Gréen H, Lotfi K, Söderkvist P.
    Eur J Haematol; 2015 Apr 15; 94(4):355-62. PubMed ID: 25156865
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
    Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Lee CP, Lin SF.
    Mol Carcinog; 2014 Dec 15; 53(12):951-9. PubMed ID: 23818300
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M.
    Clin Cancer Res; 2009 May 15; 15(10):3550-6. PubMed ID: 19451596
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
    Hofstetter G, Berger A, Bauer EM, Schuster E, Wolf A, Chamson M, Müller-Holzner E, Reimer D, Braicu EI, Sehouli J, Ulmer H, Cacsire Castillo-Tong D, Zeillinger R, Concin N.
    Oncol Rep; 2012 Mar 15; 27(3):673-7. PubMed ID: 22134502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.